Treating Patients With Breast Cancer After Progression on Endocrine Therapy

Oncologists Discuss Optimizing the Use of Elacestrant in Breast Cancer

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

Selecting Second-Line Treatment in HR+, HER2-Low Breast Cancer

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

Understanding the Significance of ESR1 Mutations in Breast Cancer

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Elacestrant Shows Greater Benefit in Endocrine-Sensitive Breast Cancer

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, looks at options for a patients with hormone receptor–positive, HER2-negative breast cancer and an ESR1 mutation in the second article of a 2-part series.

NGS and ctDNA Considered in Advanced Breast Cancer After Progression

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.

Assessing Elacestrant Across Patient Subgroups in ESR1+ Advanced Breast Cancer

During a Case-Based Roundtable® event, William J. Gradishar, MD, discussed how elacestrant benefited several subgroups of patients with metastatic breast cancer who were positive for an ESR1 mutation, along with practical considerations when addressing toxicities that arise with therapy in the second article of a 2-part series.

Elacestrant Provides Treatment Path Forward in Advanced Breast Cancer

In the first article in a 2-part series, William J. Gradishar, MD, discusses the importance of elacestrant for treating patients with ESR1 positive metastatic breast cancer.

Analyzing The Use of Elacestrant in ESR1+ Advanced Breast Cancer

In the second article of a 2-part series, Komal Jhaveri, MD, leads a discussion on the considerations physicians must have when looking to give elacestrant to patients with estrogen receptor–positive, HER2 negative metastatic breast cancer.

Oral SERDs Provide a Stronger Option in ESR1+ Advanced Breast Cancer

In the first article of a 2-part series, Komal Jhaveri, MD, guides a conversation on treatment options for patients with ESR1-positive metastatic breast cancer.

Oral SERDS Improve Survival in HR+, HER2- Metastatic Breast Cancer

In the second article of a 2-part series, Hope S. Rugo, MD, FASCO, leads a conversation on the results of the EMERLAD study that showed elacestrant’s longer survival outcomes against standard of care endocrine therapy for patients with HR+, HER2- metastatic breast cancer.

ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer

In the first article of a 2-part series, Hope S. Rugo, MD, FASCO, discusses how the use of circulating tumor DNA can aid in allowing next generation sequencing to better identify targets for patients with hormone receptor positive metastatic breast cancer.

Physicians Discuss Elacestrant Vs Alternatives in ER+, HER2- MBC

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

Physicians Discuss Modifying Use of CDK4/6 Inhibitors in ER+/HR+ Metastatic Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

Impressions of Elacestrant’s Efficacy in ER+, HER2- Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed the use of elacestrant for patients who have received prior endocrine therapy for ER-positive, HER2-negative breast cancer. This is the second of 2 articles based on this event.

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark Pegram, MD, and participants discussed their next steps for a patient with breast cancer after progression on aromatase inhibitor plus palbociclib, including repeat biomarker testing.

Comparing Elacestrant Vs Fulvestrant for ESR1-Mutated Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.

Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.

Updates on SERD Trials for Metastatic Breast Cancer

Sara Hurvitz, MD, discusses recent updates for selective estrogen receptor degraders in the treatment of patients with metastatic breast cancer and how it has impacted clinical decisions.